Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    iBio, Inc. (IBIO)

    0.7612 -0.0524 (-6.44%)
    As of 3:33:04 PM EDT. Market Open.
    Loading Chart for IBIO
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy

    iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
    GlobeNewswire 17d ago
    iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

    iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
    GlobeNewswire 1mo ago
    iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

    iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
    GlobeNewswire 2mo ago
    iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

    iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
    GlobeNewswire 3mo ago
    Could iBio (IBIO) Be an Underrated Obesity Stock?

    Could iBio (IBIO) Be an Underrated Obesity Stock?
    Insider Monkey 4mo ago
    iBio to Participate in Upcoming Healthcare Investor Conferences

    iBio to Participate in Upcoming Healthcare Investor Conferences
    GlobeNewswire 4mo ago
    iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

    iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
    GlobeNewswire 5mo ago
    iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

    iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
    GlobeNewswire 5mo ago
    iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3

    iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3
    MarketBeat 7mo ago
    iBio, Inc. (IBIO) Reports Q1 Loss

    iBio, Inc. (IBIO) Reports Q1 Loss
    Zacks 11mo ago

    iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”
    MarketBeat 6mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: